Insider Trading Activity For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
Susan E Barrowcliffe , Insider of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) reportedly Sold 6,110 shares of the company’s stock at an average price of 22 for a total transaction amount of $134,420.00 SEC Form
Insider Trading History For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
Analyst Ratings For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
These are 4 Buy Ratings .
The current consensus rating for Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is Buy (Score: 3.00) with a consensus target price of $36.25 , a potential (67.44% upside)
Analyst Ratings History For Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
- On 5/16/2016 Bank of America Corporation Reiterated Rating Buy
- On 8/19/2016 Credit Suisse Group Reiterated Rating Buy with a price target of $35.00
- On 9/26/2016 JMP Securities Initiated Coverage of rating Outperform with a price target of $30.00
- On 3/22/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $38.00
- On 7/24/2017 Wedbush Reiterated Rating Outperform with a price target of $42.00
Recent Trading Activity for Aimmune Therapeutics, Inc. (NASDAQ:AIMT)
Shares of Aimmune Therapeutics, Inc. closed the previous trading session at 21.65 down -0.35 -1.59% with 175,214 shares trading hands.